Skip to content

We envision a world where drug discovery is not left to chance but guided by artificial intelligence (AI) to make therapeutic development smarter, more precise, and ultimately faster.  We’re using iBio’s Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. 

We’re pursuing hard-to-drug targets with greater potential and less competition.  We have nine immuno-oncology candidates in our pipeline, including those for the potential treatment of solid tumors, glioblastoma, and head and neck cancers.

An essential challenge to developing antibody drugs is that traditional discovery technologies employ a high degree of randomness. Creating an antibody with a set of desired qualities requires repeated attempts until the optimal result is achieved, often by chance. While this approach has yielded valuable therapeutics in the past, that outcome is rare, with fewer than 1 in 1,000 targets ever reaching the clinic. Traditional antibody development methods are time consuming, costly, and we believe ultimately produce fewer potentially life-saving drugs than possible.  We believe that iBio’s Discovery Platform offers the precision required to solve this problem, while also identifying the most challenging targets.

iBio’s patented antibody discovery technology employs an artificial intelligence engine designed to actively guide the discovery process directly to a desired result. Our Discovery Platform is comprised of five main components:

  • Our patented AI-driven Epitope Engineering Engine, which enables the active steering of antibody discovery to desirable binding sites on the target protein
  • Our proprietary Antibody Library of fully human sequences and a clinically validated framework
  • Our StableHu™ Antibody Optimizer for generating functionally enriched libraries from a template antibody
  • EngageTx™, a CD3 T-cell engager antibody panel for optimizing next-gen bispecifics
  • ShieldTx™, an antibody masking technology for delivering on-epitope, on-tissue clinical candidates with enhanced safety and developability

By moving beyond traditional “trial-and-error” methods, we believe our platform will enable us to bring cancer therapeutics based on previously undruggable proteins into the clinic faster and more cost-effectively – both for our own development and in partnership with others.

Capitalizing on our robust AI tech platform, we’ve implemented a layered business model with three fundamental components: strategic partnerships, proprietary pipeline development, and third-party collaborations. Using this model, we intend to secure partnerships for existing molecules or discovery projects against new targets, advance select “fast followers” from our preclinical pipeline, and engage third-party collaborators in areas outside of our core therapeutic focus. We believe this approach enables iBio to grow a more focused, capital-efficient business.

Meet iBio


Meet Our Leadership Team

Martin Brenner headshot

Board of Directors